Stay updated on Eribulin + Pembrolizumab in Soft Tissue Sarcomas Clinical Trial
Sign up to get notified when there's something new on the Eribulin + Pembrolizumab in Soft Tissue Sarcomas Clinical Trial page.

Latest updates to the Eribulin + Pembrolizumab in Soft Tissue Sarcomas Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedPublication section wording updated to clarify that PubMed-listed publications are automatically populated and to note revision numbers (v3.3.2 vs v3.2.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check20 days agoChange DetectedThe page no longer displays the government funding status notice that warned about potential delays in updates. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check41 days agoChange DetectedUpdates are limited to cosmetic and layout changes and do not affect core study information such as design, eligibility criteria, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check63 days agoChange Detected- Added a government operating-status notice and links, clarifying NIH Clinical Center operations and where to check updates. - Updated version from v3.1.0 to v3.2.0.SummaryDifference2%

- Check70 days agoChange Detected- Added a new page revision tag (v3.1.0). - Removed a specific medical condition term (Undifferentiated pleomorphic sarcoma).SummaryDifference0.1%

- Check84 days agoChange DetectedPage version updated from v3.0.1 to v3.0.2 and the 'Back to Top' link was removed. No substantive content changes were detected.SummaryDifference0.1%

Stay in the know with updates to Eribulin + Pembrolizumab in Soft Tissue Sarcomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Eribulin + Pembrolizumab in Soft Tissue Sarcomas Clinical Trial page.